// App-Quantinova.ai

SAT0136 : SARILUMAB, A FULLY HUMAN MAB AGAINST IL-6R ALPHA, SUBCUTANEOUSLY-ADMINISTERED SHOWS SIGNIFICANT IMPROVEMENT IN RA PATIENTS AS EARLY AS 2 WEEKS: A TIME TO EVENT ANALYSIS FOR ACR50 AND EULAR GOOD RESPONSE

Researchers

Presenter

  • R. Fleischmann

Principal Investigators

  • S. Fiore

  • C. Fan

  • D. Thompson

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Regeneron Pharmaceut

  • Sanofi S.A.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • High sensitivity C-reactive protein

  • Interleukin 6

  • Albumin/creatinine

Drug/Treatment

  • Sarilumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved